Anúncio
relacionado a: 23andMeDiscover The Story Of Your Historic Ancestors And Find Out Your Lost Family Members. 23 And Me DNA Kits? Try Other And Better Alternatives. Top Rated DNA Ancestry Testing Kits
Resultado da Busca
Há 22 horas · SOUTH SAN FRANCISCO - 23andMe Holding Co. (NASDAQ:ME), empresa especializada en genética humana y productos biofarmacéuticos, ha comunicado datos preliminares alentadores de fase 2 sobre la ...
Há 22 horas · SOUTH SAN FRANCISCO - 23andMe Holding Co. (NASDAQ :ME), a company specializing in human genetics and biopharmaceuticals, has reported encouraging preliminary Phase 2 safety and efficacy data for its experimental drug 23ME-00610. The data was presented at the American Society of Clinical Oncology ...
Há 22 horas · 23andMe attempted to shift the blame to customers, telling them the breach was a result of customers using recycled login credentials from their accounts on other websites.Further, 23andMe then waited until December to report that 7 million customers were directly affected by the breach and didn't say anything about the data being sold on the dark web or that Jewish and Chinese customers were ...
Há 22 horas · SOUTH SAN FRANCISCO, Calif., June 03, 2024 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME) (“23andMe”), a leading human genetics and biopharmaceutical company, announced positive preliminary Phase 2 safety and efficacy data from 23ME-00610, a first-in-class anti-CD200R1 antibody, presented at the 2024 American Society of Clinical ...
Há 22 horas · U.S. District Judge Edward Chen heard arguments on Monday from more than a dozen lawyers vying for leadership of the 23andMe data breach litigation. Monday's hearing, in San Francisco, comes after ...
Há 22 horas · – 23ME-00610 monotherapy demonstrates preliminary evidence of clinical benefit, including one confirmed partial response – 23ME-00610 monotherapy continues to demonstrate acceptable safety and...
Há 22 horas · 23andMe社、癌治療薬の良好なフェーズ2データを報告. サンフランシスコ - ヒト遺伝学とバイオ医薬品を専門とする23andMe Holding Co. (NASDAQ:ME)は、実験薬23ME-00610の有望な第2相安全性・有効性予備データを報告した。. このデータは、5月31日から6月4日まで開催され ...
